8-K/A: TuHURA Completes Kineta Acquisition, Boosts Pipeline

TuHURA Biosciences, Inc. finalized its acquisition of Kineta, Inc., integrating Kineta's lead oncology asset TBS-2025 and securing significant new financing to advance its clinical pipeline.

Summary

• TuHURA Biosciences, Inc. completed the acquisition of Kineta, Inc. on June 30, 2025, as per the amended Merger Agreement dated December 11, 2024, and May 5, 2025.
• The acquisition involved a series of two mergers, with Kineta becoming a wholly-owned subsidiary of TuHURA.
• TuHURA acquired Kineta's novel KVA12123 antibody, now renamed TBS-2025, a VISTA-inhibiting monoclonal antibody.
• The merger consideration for Kineta stockholders included up to 3,998,054 shares of TuHURA Common Stock, comprising 2,868,169 initial shares and 1,129,885 delayed shares, subject to adjustment.
• No cash consideration was paid to Kineta's former shareholders at closing, as prior exclusivity payments, loans, and advances totaling $6,745,000, combined with Kineta's working capital deficit of $5,255,000, offset the base cash consideration of $12,000,000.
• Post-merger, TuHURA stockholders own approximately 92.4% and former Kineta stockholders own approximately 7.6% of the combined company.
• Kineta reported a net loss of $1.575 million for the three months ended March 31, 2025, a significant reduction from $10.249 million for the same period in 2024.
• Kineta's cash and cash equivalents decreased to $304,000 as of March 31, 2025, from $634,000 at December 31, 2024.
• TuHURA completed a private placement in June 2025, raising $12,612,169 through the sale of 4,759,309 shares and an equal number of warrants, with $8,912,151 already received and $3,700,018 committed by December 31, 2025.

Sentiment

Score: 7

Explanation: While Kineta's pre-merger financial state was dire, the acquisition by TuHURA provides a strong positive outcome for Kineta's key asset and a strategic expansion for TuHURA. The significant capital raise by TuHURA further strengthens its position to advance multiple clinical programs. The overall sentiment is positive due to strategic growth and financial strengthening, despite the acquired company's prior distress.

Positives

• TuHURA successfully acquired Kineta, integrating the promising TBS-2025 (formerly KVA12123) antibody into its pipeline.
• Kineta's net loss significantly decreased to $1.575 million for Q1 2025 from $10.249 million in Q1 2024, and net cash used in operating activities reduced from $4.011 million to $1.440 million.
• TuHURA secured substantial funding of $12.612 million through a private placement, strengthening its financial position for clinical development.
• The acquisition resolves Kineta's 'going concern' issue, providing a path forward for its assets under TuHURA's umbrella.
• TuHURA continues to advance its REM-001 study and plans to initiate a Phase 3 trial for IFx-Hu2.0 and a Phase 2 trial for TBS-2025.
• Kineta successfully divested non-core assets (Merck, Genentech, FAIR licenses to HCRX; LHF-535 to Philanthropos), streamlining its focus prior to the merger.

Negatives

• Kineta had an accumulated deficit of $184.6 million and only $304,000 in unrestricted cash as of March 31, 2025, raising substantial doubt about its ability to continue as a going concern prior to the merger.
• Kineta had paused or significantly scaled back development and commercialization of product candidates due to insufficient funding.
• Kineta was pursuing litigation or seeking settlements against certain investors for failure to fund.
• Genentech terminated its small molecule license agreement with Kineta, effective 30 days from April 15, 2025.
• No cash consideration was paid directly to Kineta's former shareholders at the closing of the merger due to prior advances and Kineta's working capital deficit.

Risks

• Substantial doubt about Kineta's ability to continue as a going concern prior to the merger, due to recurring net losses and negative cash flows.
• Uncertainty regarding the ability to obtain sufficient funds on commercially acceptable terms, which would have a material adverse effect on Kineta's business if not for the merger.
• Potential for future litigation or settlements against investors who failed to fund Kineta.
• Geopolitical developments (e.g., Ukraine, Israel/Gaza conflicts, US-China relations) may impact government spending, international trade, market stability, and macro-economic conditions, potentially affecting operations and financial results.
• Uncertainty regarding regulations and rules due to political developments, which could materially affect the company's business.
• The Disposed Asset Payment Right from Kineta's pre-closing asset sales is not currently probable and reasonably estimable due to inherent uncertainties surrounding further development, regulatory approval, or viability of agreements.
• The Delayed Share Consideration for Kineta stockholders is subject to adjustment for certain losses incurred or accrued during the six months following the merger closing.
• The final calculation of goodwill from the acquisition could differ materially from preliminary amounts due to changes in fair value estimates and actual assets/liabilities at closing.
• TuHURA anticipates no significant value derived from any other in-process research and development assets of Kintara, other than the REM-001 Study.

Future Outlook

TuHURA plans to continue advancing the clinical development of Kineta's ongoing trials, including TBS-2025 to a Phase 2 trial, while also exploring synergies with TuHURA's current ongoing studies. TuHURA anticipates successful enrollment and follow-up for the REM-001 study's Milestone by December 31, 2025, and expects to initiate a Phase 3 trial for IFx-Hu2.0. The company does not currently expect to restart or advance any other Kintara technologies acquired in the prior reverse merger.

Management Comments

• TuHURA anticipates the successful enrollment of the ten cutaneous metastatic breast cancer patients and that such patients will complete the required follow-up to complete the trials in accordance with the CVR Agreement (the Milestone).
• TuHURAs management has concluded that it is probable that the Milestone will be achieved and shares of TuHURA Common Stock will be issued.
• TuHURA currently anticipates no significant value derived from any other in-process research and development assets of Kintara.
• Other than the REM-001 Study, TuHURA does not currently expect to restart or advance any Kintara technologies that were acquired.
• Post-Mergers, TuHURA has announced that the Company will continue advancing the clinical development of Kinetas ongoing trials while also exploring the possibility of certain synergies in combination with TuHURAs current ongoing studies.

Industry Context

This acquisition reflects a trend in the biotechnology sector where larger, more financially stable companies acquire smaller, struggling clinical-stage firms to gain access to promising pipeline assets. Kineta, facing significant liquidity challenges and a 'going concern' warning, benefits from being absorbed by TuHURA, which provides the necessary capital and infrastructure to advance Kineta's lead asset, TBS-2025. For TuHURA, this expands its oncology pipeline, complementing its existing REM-001 and IFx-2.0 programs, and potentially accelerating its market presence in immunotherapy. The termination of Kineta's other license agreements and asset sales prior to the merger indicates a strategic streamlining of its portfolio, making it a more focused acquisition target.

Comparison to Industry Standards

• Kineta's financial state prior to the merger, characterized by recurring net losses, negative cash flows, and an accumulated deficit of $184.6 million, is typical for early-stage biotechnology companies that are pre-revenue and heavily invested in R&D. However, the 'going concern' warning and the need to pause/scale back R&D due to funding issues indicate a more severe liquidity crisis compared to peers that successfully secure continuous funding rounds.
• The acquisition of a clinical-stage asset (TBS-2025) for a combination of stock and prior advances, with no direct cash payment to shareholders at closing, is a common structure for distressed asset acquisitions in biotech, where the acquirer assumes the R&D burden and provides a lifeline.
• TuHURA's concurrent private placement of over $12 million is a standard method for biotech companies to fund ongoing clinical trials and acquisitions, especially when advancing programs like Phase 3 trials (IFx-Hu2.0) and Phase 2 trials (TBS-2025), which are capital-intensive.
• The divestiture of non-core assets (Merck, Genentech, FAIR licenses, LHF-535) by Kineta before the merger aligns with industry best practices for companies seeking to streamline operations or improve their attractiveness as an acquisition target by focusing on core value propositions.

Management Changes

Corporate Governance

Legal Proceedings

• Kineta is pursuing litigation or seeking other settlements against certain investors for the failure to fund.

Related Party Transactions

• No related party transactions were reported for the three months ended March 31, 2025, or 2024.

Stakeholder Impact

• Shareholders (TuHURA): Experience dilution from new share issuance for Kineta acquisition and private placement, but gain potential for increased value from an expanded pipeline and strategic growth.
• Shareholders (Kineta): Received stock consideration in TuHURA, providing a liquidity event and a path forward for their investment in a company that was facing going concern issues. No cash consideration was paid at closing.
• Employees (Kineta): Former CEO and General Counsel terminated, but received severance and continued equity vesting under consulting agreements. Other employees likely integrated or impacted by R&D scale-backs prior to merger.
• Customers/Patients: Potential benefit from continued development of TBS-2025 and other pipeline assets under TuHURA's funding and management.
• Creditors (Kineta): Some obligations settled through equity issuance prior to merger, and notes payable were part of the merger consideration.
• Suppliers/Vendors (Kineta): Some outstanding obligations were settled through equity or cash as part of meeting closing conditions.

Next Steps

• TuHURA to continue advancing the clinical development of TBS-2025 (formerly KVA12123) to a Phase 2 trial.
• TuHURA to continue the REM-001 study, aiming for successful enrollment of 10 patients and completion of required follow-up by December 31, 2025.
• TuHURA to evaluate whether the REM-001 technology has potential future value after completing the NIH-funded trial.
• TuHURA plans to initiate a Phase 3 trial for IFx-Hu2.0.
• TuHURA to receive remaining $3,700,018 from June 2025 Private Placement by December 31, 2025.
• TuHURA to file a registration statement for resale of shares and warrants from June 2025 Private Placement within 60 calendar days of June 4, 2025, and aim for effectiveness within 120 calendar days.
• Kineta stockholders to receive Delayed Per Share Stock Consideration after six months following the closing of the Mergers, subject to adjustment.
• Kineta stockholders may receive pro rata share of cash from Disposed Asset Payment Right if certain conditions are met.

Key Dates

Recommendation

The acquisition of Kineta, while strategically sound for pipeline expansion, involves integrating a financially distressed entity. TuHURA's significant capital raise is positive, but the company is still in early clinical stages with its key assets (REM-001, TBS-2025, IFx-Hu2.0). The future value is highly dependent on successful clinical trial outcomes and regulatory approvals, which carry substantial risk. Given the early stage of development and the inherent uncertainties in biotech, a 'hold' recommendation is appropriate for investors to observe progress on the clinical milestones and the integration of the acquired assets before making further investment decisions.

Keywords

TuHURA Biosciences, Kineta, Acquisition, Merger, Biotechnology, Immunotherapy, TBS-2025, KVA12123, Clinical Trials, REM-001, IFx-2.0, Private Placement, Capital Raise, Financial Results, Corporate Governance, Risk Management, SEC, NASDAQ